|
1. Schedule A is to be used for small-cell lung cancer, non-small-cell lung cancer, breast cancer (inoperable or recurrent), and squamous cell carcinoma. Schedule A or B is to be for cervical cancer, ovarian cancer, gastric cancer (inoperable or recurrent), and colorectal cancer (inoperable or recurrent). Schedule C is to be used for malignant lymphoma (non-Hodgkin's lymphoma). Schedule D is to be used for pediatric cancer. Schedule E is to be used for unresectable pancreatic cancer.
A: Normally adults are given 100 mg/m2 of irinotecan hydrochloride once a day, three or four times, weekly by intravenous infusion; the drug is then discontinued for at least 2 weeks. This constitutes one course of the therapy, and the course is repeated.
B: Normally adults are given 150 mg/m2 of irinotecan hydrochloride once a day, two or three times, every 2 weeks by intravenous infusion; the drug is then discontinued for at least 3 weeks. This constitutes one course of the therapy, and the course is repeated.
C: Normally adults are given 40 mg/m2 of irinotecan hydrochloride once a day, for three consecutive days by intravenous infusion. This is repeated at weekly cycles for two to three consecutive weeks; the drug is then discontinued for at least 2 weeks. This constitutes one course of the therapy, and the course is repeated.The dose of the drug for treatment methods A to C may be increased or decreased as is appropriate for the patient’s age and symptoms.
D: Normally children are given 20 mg/m2 of irinotecan hydrochloride once a day, for five consecutive days by intravenous infusion. This is repeated at weekly cycles for two consecutive weeks; the drug is then discontinued for at least 1 weeks. This constitutes one course of the therapy, and the course is repeated.
E: Normally adults are given 180 mg/m2 of irinotecan hydrochloride once a day by intravenous infusion. The drug is then discontinued for at least 2 weeks. This constitutes one course of the therapy, and the course is repeated.
The dose of the drug for treatment methods D and E may be decreased as is appropriate for the patient’s age and symptoms.
2. When given under Schedule A, B and E, the drug should be mixed, at the time of administration with 500 mL or more of physiologic saline, glucose solution, or electrolyte maintenance solution, and infused over a period of 90 minutes or longer.
When using Schedule C, each dose should be mixed, at the time of administration with 250 mL or more of physiologic saline, glucose solution, or electrolyte maintenance solution and infused over a period of 60 minutes or longer.
When using Schedule D, each dose should be mixed, at the time of administration with 100 mL or more of physiologic saline, glucose solution, or electrolyte maintenance solution and infused over a period of 60 minutes or longer.
|